# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
UBS analyst Colin Bristow maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and lowers the price target from $14 to $6.
HC Wainwright & Co. analyst Andrew Fein reiterates Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and maintains $15 pri...
Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate...
Sabirnetug is the first humanized monoclonal antibody to clinically demonstrate selective target engagement of AβOs in AD patie...
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targ...
Citigroup analyst David Hoang initiates coverage on Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy rating and announces Pri...
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targ...
HC Wainwright & Co. analyst Andrew Fein reiterates Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and maintains $15 pri...